@FierceMedDev: Accuray rebound continues with strong second-quarter results Story | Follow @FierceMedDev
@MarkHFierce: Medtronic's Infuse bone growth product continues to generate legal problems. Report via MassDevice | Follow @MarkHFierce
@GalenMoore: At VentureCafe today: quantumvr's handheld 3D scanner. Design, sure, but could it be used for diabetes? Photo | Follow @GalenMoore
@MichaelGFierce: Nanogold 'superstructures' are held together with DNA for #cancer drug delivery. More | Follow @MichaelGFierce
@EmilyWFierce: FDA considering faster approval process for high-need medical devices. Report via MedPageToday | Follow @EmilyWFierce
> Zimmer ($ZMH) is suing a former employee and Stryker ($SYK) in Indiana federal court, alleging that both concocted a plan to steal trade secrets and poach Zimmer employees. Story (sub. req.)
> Medtronic ($MDT) faces a setback in a product liability lawsuit regarding its Infuse bone-growth protein. A California appeals court reversed a lower court decision that stated federal regulations in the case preempted state rules. Story
> Canada's regulators are mulling plans to amend the country's drug and medical device law, adding the ability to order product recalls and label changes after a health risk becomes clear. Item
> Some are calling for a decrease in the use of medical imaging with high-dose radiation, as well as better guidelines to determine acceptable levels of exposure. Opinion (subs. req)
> Biomeme in Philadelphia raised nearly $1 million in a debt financing to advance development of technology that turns smartphones into low-cost diagnostic labs. Story
Biotech News
@FierceBiotech: Bioinformatics skills help Stanford beat Illumina to $40M stell cell genomics grant. Story from FierceBiotechIT | Follow @FierceBiotech
@JohnCFierce: Amgen clocks 5th straight win on PCSK9, well ahead of the competition. Credit where it's due - they went all out. Story | Follow @JohnCFierce
@DamianFierce: AbbVie's hep C program is in desperate need of a catchy nickname. "ABT-450/r + ABT-267 + ABT-333" less than rolls off the tongue. | Follow @DamianFierce
@EmilyMFierce: Exposure to acid turns regular adult cells into stem cells. Story from FierceBiotechResearch | Follow @EmilyMFierce
> AbbVie's hep C hopeful aces PhIII and sets off an arms race with Gilead. Story
> Two biotech IPOs blast off, spurring dreams--and fears--of an attempted gold rush. Article
> Sanofi blocks Eli Lilly's biosimilar of Lantus at the goal line, buys time. Story
> Amgen outpaces its rivals in the race for a PCSK9 blockbuster. News
> Wellcome ponies up $20M to kick-start an Oxford spinout. Article
Pharma News
@FiercePharma: Daiichi Sankyo pledges 'drastic measures' to get Ranbaxy in line. Story | Follow @FiercePharma
@TracyStaton: BMS counts on DTC to keep driving Eliquis growth. But are its ads much different from rivals? News | Follow @TracyStaton
@EricPFierce: Lilly announced 1,000 job cuts in 2013. 2014 expected to be even bleaker. Report | Follow @EricPFierce
@CarlyHFierce: Sanofi wards off Lilly's Lantus challenger with infringement lawsuit. More | Follow @CarlyHFierce
> Abbott Labs cuts jobs at HQ and plans for plant closure in Puerto Rico. News
> Sanofi wards off Lilly's Lantus challenger with infringement lawsuit. Story
> Daiichi Sankyo pledges 'drastic measures' to get Ranbaxy in line. More
> Amgen cutting 200 jobs despite improved Epogen sales. Item